461719-98-2

Upstream product

• 54054-85-2 1-(3-nitrophenyl)piperazine 
• 5891-45-2 (S)-2-(benzyloxycarbonylamino)pentanedioic acid tert-butyl ester 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 294210-79-0 1-(3-nitrophenyl)piperazine monohydrochloride 

Downstream Products

• 1408226-89-0 C₄₂H₅₈N₆O₁₁ 
• 1408227-13-3 C₄₃H₆₀N₆O₁₁ 
• 1408227-10-0 C₂₉H₃₈N₄O₇ 
• 461720-00-3 (2S)-2-benzyloxycarbonylamino-5-[4-[3-[1,3-bis(tertbutoxycarbonyl)hexahydropyrimidin-2-ylidene]aminophenyl]piperazin-1-yl]-5-oxopentanoic acid tert-butyl ester 
• 461719-99-3 5-[4-(3-amino-phenyl)-piperazin-1-yl]-2-benzyloxycarbonylamino-5-oxo-pentanoic acid tert-butyl ester 

Relevant academic research and scientific papers

Camptothecins in tumor homing via an RGD sequence mimetic

A RGD peptide mimetic was conjugated to four camptothecins, with the purpose to improve their therapeutic index. The conjugate derivatives were evaluated against two tumor cell lines, one overexpressing integrins (human ovarian carcinoma, A2780) and a sec

Discovery of a potent and selective αvβ3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model

A new series of phenylpiperazine-based derivatives with strong antagonistic activity for αvβ3 integrin were synthesized. Of these derivatives, the fluorine-substituted compound 8 showed strong inhibitory activity and high selectivity for αvβ 3 integrin receptor (IC50=0.055nM). In vivo evaluation of the antistenotic effects of 8 indicated that this compound significantly inhibits neointima formation in rat balloon injury model.